🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase III

Metabolic & obesity programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
227

Quick answer

Metabolic & obesity Phase III programs: NovaPharmaNews indexes 227 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 1 of 5

  1. 2-mg Intravitreous Aflibercept Injection

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  2. 2.0 mg intravitreal aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  3. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  4. AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide

    Amgen

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  5. AMG 133, Placebo for AMG 133, AMG 133, AMG 133

    Amgen

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  6. Aflibercept

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  7. Aleglitazar

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    2 trials

  8. Alirocumab

    Regeneron UK Limited

    Type2 Diabetes

    phase 3 small molecule completed

    1 trial

  9. Alogliptin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    9 trials

  10. Alogliptin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  11. Alogliptin Benzoate

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  12. Alogliptin and glimepiride

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  13. Alogliptin and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  14. Alogliptin and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  15. Alogliptin and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  16. Alogliptin and metformin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  17. Alogliptin and pioglitazone

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  18. Alogliptin and pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  19. Alogliptin and voglibose

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  20. Aramchol free acid

    Galmed Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 3 small molecule on hold

    1 trial

  21. BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  22. BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  23. BAT5906 injection

    Bio-Thera Solutions

    Diabetic Macular Edema (DME)

    phase 3 small molecule active

    1 trial

  24. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  25. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  26. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  27. BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  28. BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  29. BT-001

    CATALYST PHARMACEUTICALS, INC.

    Type2 Diabetes

    phase 3 other terminated

    1 trial

  30. Betamethasone Microsphere (DE-102） Low Dose

    Santen Oy

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  31. Bevacizumab

    Hospital Authority, Hong Kong

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  32. Biological/Vaccine

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 3 mab active

    1 trial

  33. Botulinum toxin type A

    Hospital Authority, Hong Kong

    Obesity

    phase 3 small molecule active

    1 trial

  34. CKD-501 0.5mg

    Hong Kong Baptist University

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  35. CSII (Insulin Pump) plus DAFNE

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 3 other completed

    1 trial

  36. Cadisegliatin 800 mg QD

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  37. Canagliflozin

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  38. Capsaicin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Polyneuropathy

    phase 3 small molecule completed

    1 trial

  39. DIAMICRON 60MG, comprimé sécable à libération modifiée, Placebo S05762, METFORMIN, Forxiga 10 mg film-coated tablets

    The George Institute

    Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin

    phase 3 small molecule active

    1 trial

  40. DULAGLUTIDE , Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  41. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  42. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    3 trials

  43. Dapagliflozin 10 mg

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

    phase 3 small molecule completed

    1 trial

  44. Dapagliflozin 10 mg

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  45. Duloxetine hydrochloride

    Eli Lilly and Company

    Diabetic Neuropathies

    phase 3 small molecule completed

    1 trial

  46. EMPAGLIFLOZIN , DAPAGLIFLOZIN , INSULIN GLARGINE , Placebo to match LY3502970, METFORMIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  47. Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity

    NovoThirteen

    Overweight and obesity

    phase 3 other active

    1 trial

  48. Eloralintide

    Eli Lilly and Company

    Obesity

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity Phase III programs exist?

227 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.